ZM484
ZM484 is a potent dual p53-MDM2/TOP1 inhibitor that exhibits antiproliferative and antitumor activity both in vitro and in vivo. ZM484 effectively upregulates p53 and MDM2 proteins and maintains TOP1 inhibitory activity by the release of camptothecin (CPT) and a potent p53-MDM2 inhibitor. ZM484 induces cell cycle arrest and apoptosis by regulating the expression of key apoptosis- and cycle-related proteins, including caspase-3, Bcl-2, and Cyclin B1. ZM484 can be used for colorectal cancer research.
For research use only. We do not sell to patients.
- Formula: C67H72Cl2F2N6O15S2
- Molecular Weight:1374.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
ZM484 (72 h) shows potent antiproliferative activity against three cancer cell lines HCT116, SJSA-1, and A549 with IC50 values of 0.03, 0.97, and 0.11 μM, respectively[1].
ZM484 (1.56-50 μM, 72 h) exhibits minimal cytotoxicity towards the noncancerous MRC-5 cell line[1].
ZM484 (3.125-100 μM, 30 min) shows no hemolytic activity at a concentration of 100 μM[1].
ZM484 (50 μM, 0-24 h) maintains an amount concentration of over 95% within 24 h, and exhibits excellent stability even in acidic buffer solutions with pH values of 2 or 5[1].
ZM484 (25-100 nM, 8 days) significantly reduces the colony formation ability of HCT116 cells[1].
ZM484 (0.195-200 μM, 15 min) inhibits TOP1 activity in a concentration-dependent manner, retaining efficacy at concentrations as low as 0.195 μM[1].
ZM484 (50-100 nM, 4 h) upregulates p53 and MDM2 protein levels in a concentration-dependent manner[1].
ZM484 (10-40 nM, 24 h) effectively induces cell cycle arrest in HCT116 cells in the S and G2 phases[1].
ZM484 (10-640 nM, 48 h) exhibits a potent, concentration-dependent proapoptotic effect in HCT116 cells, which is concomitant with a dose-dependent decrease in the expression levels of caspase-3, Bcl-2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells
-
Concentration:25, 50, and 100 nM
-
Incubation Time:8 days
-
Result:Significantly reduced the colony formation ability of HCT116 cells at concentrations of 25, 50, and 100 nM.
-
Cell Line:HCT116 cells
-
Concentration:50 and 100 nM
-
Incubation Time:4 h
-
Result:Increased p53 and MDM2 protein levels in a concentration-dependent manner.
Exhibited more activity than Idasanutlin (HY-15676) at 50 and 100 nM for p53 protein upregulation.
-
Cell Line:HCT116 cells
-
Concentration:10 and 40 nM
-
Incubation Time:24 h
-
Result:Induced a dose-dependent increase in the S phase (29.8% and 43.3% at 10 and 40 nM, respectively) and G2 phase (20.9% and 28.3%) cell populations.
-
Cell Line:HCT116 cells
-
Concentration:40, 160, and 640 nM
-
Incubation Time:48 h
-
Result:Induced significant apoptosis in a concentration-dependent manner, with apoptotic rates of 11.6%, 16.8%, and 25.8% at concentrations of 40, 160, and 640 nM, respectively.
Induced apoptosis more effectively than Idasanutlin or the vehicle control.
Decreased the expression levels of caspase-3, Bcl-2 in a dose-dependent manner.
Parmacokinetics
| Species | Dose | Route | AUCall | AUCinf | T1/2 | CL | Vss | MRTINF_obs |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 5 mg/kg | i.v. | 2600 ng·h/mL | 2799 ng·h/mL | 1.65 h | 30.1 mL/min/kg | 1339 mL/kg | 0.73 h |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice (4-6 weeks) subcutaneously injected with HCT116 cells[1]
-
Dosage:10 mg/kg
-
Administration:i.p., every other day for 12 days
-
Result:Exhibited the highest tumor growth inhibition (TGI of 81.07%) among the tested groups, surpassing the positive controls Idasanutlin (25 mg/kg, i.g., qd, TGI = 68.59%) and Irinotecan (HY-16562) (50 mg/kg, i.p., qw, TGI = 64.01%).
Chemical Information
-
Molecular Weight 1374.35
-
Formula C67H72Cl2F2N6O15S2
-
SMILES
O=C1C2=C(C=C3C4=NC5=CC=CC=C5C=C4CN31)[C@](OC(OCCSSCCOC(CCOCCOCCOCCOCCNC(C6=CC(OC)=C(NC([C@@H]([C@@H]([C@]7(C8=C(C=C(C=C8)Cl)F)C#N)C9=CC=CC(Cl)=C9F)N[C@H]7CC(C)(C)C)=O)C=C6)=O)=O)=O)(C(OC2)=O)CC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)